Prestige Consumer Healthcare (NYSE:PBH) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research report released on Tuesday morning.

Several other brokerages also recently weighed in on PBH. Canaccord Genuity Group increased their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. DA Davidson increased their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Finally, Oppenheimer increased their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and an average target price of $92.60.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $84.01 on Tuesday. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 19.67, a PEG ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $90.04. The business has a 50 day simple moving average of $81.87 and a 200-day simple moving average of $78.45. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Equities analysts forecast that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of PBH. Kestra Investment Management LLC bought a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $27,000. CIBC Private Wealth Group LLC boosted its position in Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after acquiring an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $40,000. Huntington National Bank boosted its position in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after acquiring an additional 181 shares in the last quarter. Finally, McIlrath & Eck LLC boosted its position in Prestige Consumer Healthcare by 19.1% during the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after acquiring an additional 154 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.